Abstract:ABSTRACT Non-tuberculosis mycobacteria (NTM), particularly Mycobacterium abscessus subsp. abscessus ( M. abscessus ), are increasingly being recognized as etiological agents of NTM pulmonary disease. However, treatment options for M. abscessus are limited owing to their natural resistance to most antibiotics, including β-lactams. M. abscessus produces a class A β-lactamase, whose activity is inhibited by cyclic boronic acid β-lactamase inhibitors. We aimed to evaluate the in vitro effects of xeruborbactam, a cyclic boronic acid β-lactamase inhibitor, against M. abscessus when combined with five β-lactams (amoxicillin, tebipenem, cefdinir, cefuroxime, and cefoxitin). The drug susceptibilities of 43 M . abscessus clinical isolates obtained from 43 patients between August 2005 and May 2014 were tested. The MIC results for each β-lactam with or without 4 μg/mL xeruborbactam were examined. Xeruborbactam lowered the MIC 90 values of tebipenem, amoxicillin, cefuroxime, and cefdinir by 5, ≥4, 3, and 3 dilutions, respectively. The MIC 90 values of cefoxitin without xeruborbactam were 32 μg/mL and did not change upon the addition of xeruborbactam. The lowest MIC 90 value was obtained for tebipenem with xeruborbactam. Almost all isolates had an MIC of 4 μg/mL; one isolate had an MIC of 2 μg/mL. With respect to the susceptibility to the same family drug, the number of susceptible isolates increased from 1/43 (2%) to 43/43 (100%) for tebipenem with xeruborbactam. Combining tebipenem and xeruborbactam could be considered an effective all-oral regimen that benefits outpatient treatment of M. abscessus pulmonary disease. IMPORTANCE Mycobacterium abscessus subsp. abscessus ( M. abscessus ) disease is treated in two phases; injectable drugs for initial followed by others for continuation. There is a need to develop all-oral treatment methods for M. abscessus infection, especially in the continuation phase. However, treatment options for M. abscessus are limited owing to their natural resistance to most antibiotics. This is the first report to evaluate the in vitro effects of xeruborbactam, a cyclic boronic acid β-lactamase inhibitor capable of inhibiting the class A β-lactamase produced by M. abscessus , against 43 M. abscessus clinical isolates when combined with five β-lactam antibiotics. Xeruborbactam lowered the MIC90 values of tebipenem by five dilutions, and the number of susceptible isolates increased from 1/43 (2%) to 43/43 (100%). We showed that the tebipenem-xeruborbactam combination might be of interest to explore further as a potentially effective oral regimen for outpatient treatment of M. abscessus pulmonary disease.

Aryl‐fluorocyclopropane β‐lactams with activity against Mycobacteroides abscessus and Mycobacterium bovis BCG

Broad-Spectrum In Vitro Activity of Nα-aroyl-N-aryl-Phenylalanine Amides against Non-Tuberculous Mycobacteria and Comparative Analysis of RNA Polymerases

Synthesis and structure-activity relationships of aryl fluorosulfate-based inhibitors as novel antitubercular agents

Synthesis and antibacterial activity of C2-fluoro, C6-carbamate ketolides, and their C9-oximes

An anti-mycobacterial conjugated oligoelectrolyte effective against Mycobacterium abscessus

Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases

In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species

Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus

Design, synthesis, biological evaluation and in silico studies of certain aryl sulfonyl hydrazones conjugated with 1,3-diaryl pyrazoles as potent metallo-β-lactamase inhibitors

In vitro effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical Mycobacterium abscessus isolates

Anti-biofilm activity of new low molecular weight compounds produced by Lactiplantibacillus plantarum SJ33 against Klebsiella pneumoniae

An arylsulphonamide that targets cell wall biosynthesis in Mycobacterium tuberculosis

Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro .

Identification of a 2‐aminobenzimidazole scaffold that potentiates gram‐positive selective antibiotics against gram‐negative bacteria

Antimicrobial and Antibiofilm Effects of Bithionol against Mycobacterium abscessus

In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1,2,4-oxadiazole analogues against Mycobacterium tuberculosis

An arylsulfonamide that targets cell wall biosynthesis in Mycobacterium tuberculosis

Design, Synthesis, Antibacterial and Antitubercular Studies of Some New Benzimidazoles. A Combined Experimental and Computational Approach

In vitro and intracellular activity of vaborbactam combined with β-lactams against Mycobacterium abscessus

Pyrrole‐Thiazolidin‐4‐one Analogues Exhibit Promising Anti‐Tuberculosis Activity

Novel Teixobactin Analogues Show Promising In Vitro Activity on Biofilm Formation by Staphylococcus aureus and Enterococcus faecalis